What insider share sales did Pharvaris (PHVS) disclose in this Form 4?

A Pharvaris director reported selling 37,600 common shares across two days. He sold 6,888 shares on June 29, 2026 and 30,712 shares on June 30, 2026 in open-market transactions executed under a Rule 10b5-1 trading plan.

Pharvaris (PHVS) director sells 37,600 shares in Rule 10b5-1 plan

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Pharvaris N.V. director Johannes Gerardus Christiaan Petrus Schikan reported open-market sales of company common stock under a pre-arranged Rule 10b5-1 trading plan. He sold 6,888 shares on June 29, 2026 at a weighted average price of $35.0533 per share and 30,712 shares on June 30, 2026 at a weighted average price of $35.4926 per share.

Following these transactions, he directly holds 315,167 Pharvaris common shares. Footnotes state that both sales were executed through multiple trades within daily price ranges of $35.00–$35.10 and $35.00–$35.90, respectively, and were carried out pursuant to his Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Net Seller: 37,600 shares ($1,331,496)

Net Sell 2 txns

Insider Schikan Johannes Gerardus Christiaan Petrus

Role null

Sold 37,600 shs ($1.33M)

Type	Security	Shares	Price	Value
Sale	Common Stock	30,712	$35.4926	$1.09M
Sale	Common Stock	6,888	$35.0533	$241K

Holdings After Transaction: Common Stock — 315,167 shares (Direct, null)

Footnotes (1)

This is a scheduled sale from 10b5-1 trading plan. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.10 The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.90. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold June 29, 2026: 6,888 shares Price June 29, 2026: $35.0533 per share Shares sold June 30, 2026: 30,712 shares +5 more

8 metrics

Shares sold June 29, 2026 6,888 shares Open-market sale of common stock

Price June 29, 2026 $35.0533 per share Weighted average sale price

Shares sold June 30, 2026 30,712 shares Open-market sale of common stock

Price June 30, 2026 $35.4926 per share Weighted average sale price

Total shares sold 37,600 shares Net sales across both days

Shares owned after sales 315,167 shares Director’s direct holdings post-transaction

Price range June 29, 2026 $35.00–$35.10 Intraday sale price range per footnote

Price range June 30, 2026 $35.00–$35.90 Intraday sale price range per footnote

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"sales were made pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The reported price represents a weighted average sale price"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 07:06 PM Accepted by SEC EDGAR 07/01/2026 - 07:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schikan Johannes Gerardus Christiaan Petrus

(Last)

(First)

(Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON

MASSACHUSETTS

02421

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/29/2026		S⁽¹⁾		6,888	D	$35.0533⁽²⁾	345,879	D
Common Stock	06/30/2026		S⁽¹⁾		30,712	D	$35.4926⁽³⁾	315,167	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This is a scheduled sale from 10b5-1 trading plan.

2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.10 The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.90. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

	/s/ Marnus Nel, Attorney-in-Fact for Johannes Schikan	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

Who is the Pharvaris (PHVS) insider selling shares and what is his role?

The insider is Johannes Gerardus Christiaan Petrus Schikan, a director of Pharvaris N.V. The Form 4 shows his open-market sales of company common stock while continuing to hold a substantial direct position in Pharvaris shares after the reported transactions.

At what prices did the Pharvaris (PHVS) director sell his shares?

The director’s reported weighted average sale prices were $35.0533 on June 29, 2026 and $35.4926 on June 30, 2026. Footnotes explain that each figure is an average for multiple trades executed within daily price ranges around $35.00 per share.

How many Pharvaris (PHVS) shares does the director hold after these sales?

After the reported open-market sales, the director directly owns 315,167 Pharvaris common shares. This post-transaction holding, disclosed in the Form 4, indicates he retains a significant equity stake in the company despite the recent scheduled sales.

Were the Pharvaris (PHVS) insider sales part of a Rule 10b5-1 plan?

Yes. Footnotes state the sales were made pursuant to a Rule 10b5-1 trading plan. Such plans are pre-arranged programs that schedule trades in advance, helping insiders systematically sell shares without making ad hoc timing decisions based on nonpublic information.